Humacyte’s (HUMA) “Overweight” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Humacyte (NASDAQ:HUMA) in a research note issued to investors on Tuesday morning, Benzinga reports. The firm currently has a $7.00 price target on the stock.

Several other research analysts have also commented on HUMA. Benchmark restated a buy rating and set a $15.00 price target on shares of Humacyte in a research note on Tuesday. Piper Sandler restated a neutral rating and set a $4.00 price target on shares of Humacyte in a research note on Tuesday, March 26th.

Humacyte Stock Down 4.8 %

HUMA stock opened at $5.11 on Tuesday. Humacyte has a 12-month low of $1.96 and a 12-month high of $9.97. The company has a quick ratio of 8.37, a current ratio of 8.37 and a debt-to-equity ratio of 0.61. The company has a market cap of $608.50 million, a price-to-earnings ratio of -5.11 and a beta of 1.52. The company has a 50 day moving average of $5.95 and a two-hundred day moving average of $4.22.

Humacyte (NASDAQ:HUMA) last released its earnings results on Friday, May 10th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). On average, equities analysts anticipate that Humacyte will post -0.95 earnings per share for the current fiscal year.

Insider Activity at Humacyte

In related news, COO Heather Ledbetter Prichard sold 188,886 shares of the firm’s stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $8.14, for a total value of $1,537,532.04. Following the transaction, the chief operating officer now directly owns 2,625 shares in the company, valued at approximately $21,367.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, Director Brady W. Dougan sold 271,518 shares of the firm’s stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $7.30, for a total value of $1,982,081.40. Following the transaction, the director now directly owns 4,559,140 shares in the company, valued at approximately $33,281,722. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Heather Ledbetter Prichard sold 188,886 shares of the firm’s stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $8.14, for a total transaction of $1,537,532.04. Following the completion of the transaction, the chief operating officer now owns 2,625 shares in the company, valued at $21,367.50. The disclosure for this sale can be found here. In the last three months, insiders have bought 54,412 shares of company stock worth $369,107 and have sold 1,628,820 shares worth $12,464,121. 23.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. SG Americas Securities LLC grew its position in Humacyte by 52.8% in the 4th quarter. SG Americas Securities LLC now owns 16,340 shares of the company’s stock worth $46,000 after purchasing an additional 5,645 shares during the last quarter. Tower Research Capital LLC TRC grew its position in Humacyte by 261.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,989 shares of the company’s stock worth $26,000 after purchasing an additional 6,504 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in Humacyte by 65.9% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 19,883 shares of the company’s stock worth $62,000 after purchasing an additional 7,897 shares during the last quarter. Powell Investment Advisors LLC grew its position in Humacyte by 75.0% in the 4th quarter. Powell Investment Advisors LLC now owns 21,000 shares of the company’s stock worth $60,000 after purchasing an additional 9,000 shares during the last quarter. Finally, Whittier Trust Co. of Nevada Inc. acquired a new stake in Humacyte in the 4th quarter worth $28,000. 44.71% of the stock is currently owned by institutional investors and hedge funds.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.